Our Company2024-05-22T18:28:12+00:00

A new approach to treating coronary artery disease.

Our Company

Woman in sweater talking to doctor, who is holding a clipboard

We’re on a mission to prevent heart attacks.

At Abcentra, we are a clinical-stage biopharmaceutical company focused on bringing new and better treatment options to patients with coronary artery disease, with the aim of preventing heart attacks.

Our team is pioneering the concept of oxidized low-density lipoprotein (OxLDL) inhibition – a selective way to target coronary artery inflammation. OxLDL inhibition has promise to target coronary inflammation in a highly specific manner, thereby maximizing the potential benefit to patients and minimizing treatment-associated risks.

Our clinical-stage product, Orticumab, is a first-in-class oxLDL inhibitor antibody therapy that has now demonstrated the potential to reduce coronary inflammation in a phase 2a study.  We are developing Orticumab for secondary prevention after an acute coronary syndrome (ACS), with further plans to expand use into coronary artery disease patients with elevated coronary inflammation.

Our Pipeline

We are developing orticumab to decrease risk of a heart attack in patients with coronary artery disease and inflammation.

Abcentra Pipeline graphic showing the current status of two developmental applications for Orticumab in Phase 2

Our Leadership Team

Meet the leading scientists, business leaders, and passionate advocates leading Abcentra’s executive team and Board of Directors.

Headshot of Chris Farina, Abcentra CEO
Chris Farina, M.S. RAC

Chief Executive Officer

Headshot of Chris Farina, Abcentra CEO
Chris Farina
Jan Nilsson Headshot
Jan Nilsson, M.D., PhD

Chief Scientific Officer & Board Member

Jan Nilsson Headshot
Jan Nilsson, M.D., PhD
Headshot of Kevin Melvin
Kevin Melvin, BS, CMP

Vice President, Clinical Operations

Headshot of Kevin Melvin
Kevin Melvin, BS, CMP
Todd Villenes Headshot
Todd C. Villines, MD, FACC, FAHA, MSCCT

Executive Medical Director

Todd Villenes Headshot
Todd C. Villines, MD, FACC, FAHA, MSCCT
Ryan Abbott Headshot
Ryan Abbott, M.D., J.D.

General Counsel

Ryan Abbott Headshot
Ryan Abbott, M.D., J.D.
Prediman Shah Headshot
Prediman K. Shah, M.D.

Founding Scientist & Board Member

Prediman Shah Headshot
Prediman K. Shah, M.D.
John Farina Headshot
John Farina

Chairman of the Board

John Farina Headshot
John Farina
Michael Davidson Headshot
Michael H. Davidson, M.D.

Board Member

Michael Davidson Headshot
Michael H. Davidson, M.D.
Timothy Wright Headshot
Timothy Wright, M.D.

Board Member

Timothy Wright Headshot
Timothy Wright, M.D.
Willem Mesdag Headshot
Willem Mesdag

Board Member

Willem Mesdag Headshot
Willem Mesdag
Edward Pruchunas Headshot
Edward M. Prunchunas

Board Member

Edward Pruchunas Headshot
Edward M. Prunchunas
Dr. Nehal Mehta Headshot
Nehal Mehta, M.D.

Medical Advisor

Dr. Nehal Mehta Headshot
Nehal Mehta, M.D.
Four headshots of Abcentra leadership arrange into a fan with grey connecting lines. CEO Chirs Farina at the center.
White quotation marks

Our mission to combat arterial inflammation isn’t just about developing a drug, it is about rewriting the narrative around cardiovascular health. We believe in a future where the message of every heartbeat is vitality – not vulnerability.

Chris Farina – CEO, Abcentra

Our Advisors & Investors

Our success is the culmination of many partnerships, relationships, and investments. Meet some of our most important advisors and investors.

Full color logo of Cedars Sinai
Cedars Sinai

Investor

Full color logo of Cedars Sinai
Cedars Sinai
Full color logo of Glenbarr Partners
Glenbarr Partners

Investor

Full color logo of Glenbarr Partners
Glenbarr Partners

Interested in Partnership Opportunities?

Reach out to us today to explore partnership opportunities and join us in creating the future of treatment for coronary artery disease.

frequently asked questions

What is Abcentra’s mission?2024-03-27T00:27:50+00:00

Put simply, we are on a mission to prevent heart attacks.

At Abcentra, we are focused on bringing new and better treatment options to patients with coronary artery disease, with the aim of preventing heart attacks. Leveraging our knowledge of coronary artery disease and the role that inflammation plays in causing a heart attack, we are developing a new class of pharmaceutical treatments that is highly differentiated from today’s treatment options.

Where is Abcentra’s corporate headquarters?2024-03-12T14:30:24+00:00

We are based in Los Angeles, California. For more specific information on our office address, please visit the Contact Us page.

Who are the members of Abcentra’s Board of Directors?2024-03-12T14:36:21+00:00

The current members of the Board of Directors are:

  • John Farina, Chairman
  • Dr. Michael Davidson
  • Dr. Timothy Wright
  • Dr. Prediman Shah
  • Dr. Jan Nilsson
  • Willem Mesdag
  • Edward Prunchunas
Who are the members of Abcentra’s management team?2024-03-30T00:01:11+00:00

Our company is led by:

  • Chris Farina, Chief Executive Officer
  • Jan Nilsson, Chief Scientific Officer
  • Kevin Melvin, Vice President of Clinical Operations
  • Ryan Abbott, General Counsel
Go to Top